Tanja Schjødt Jørgensen received her master in Human Physiology in Sport and Exercise in 2007 from the University of Copenhagen, conducting her master thesis on the effects of training in knee osteoarthritis patients. In 2009 Dr Schjødt Jørgensen was enrolled as a Ph.D. student at the Center for Sensory-Motor Interaction (SMI) at Aalborg University, Denmark, in collaboration with the Parker Institute, Copenhagen, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Denmark.
The title of the Ph.D. is: “Contributions to the understanding of osteoarthritis pain”. The overarching aim of the thesis is to provide more in-depth knowledge about pain mechanisms in knee osteoarthritis (OA), to optimally treat this common disease. Pain is the cardinal symptom of knee OA, and currently this disease cannot be cured. Pain and disability are prominent clinical features of knee OA. Some of the mechanisms underlying the pain are unknown. Especially, knowledge of how joint pain affects the pain systems will provide important new insight and help to explain the basic pain mechanisms in humans. Hopefully, the results of this thesis might contribute to development of more rational therapies of the pain mechanisms, when targeting pain relief in individuals with knee OA. Tanja defended her Ph.D. in january 2015.
Since April 2013 Tanja Schjødt Jørgensen has been employed at the Parker Institute, Musculoskeletal Statistics Unit, as a researcher, focusing on treatment strategies in rheumatoid arthritis (RA) and evaluating the optimal medical treatment of RA, based on efficacy, drug survival, side effects and cost. She has participated as a project coordinator in a multicentre study in collaboration with the Departments of Rheumatology in Denmark and the nationwide Danish DANBIO registry. In the study Tanja Schjødt Jørgensen has focused on elucidating the prevalence of Danish RA patients currently on biologic monotherapy and compare effectiveness and drug adherence of the biologic therapies applied as monotherapy in Danish RA patients.
In addition Tanja Schjødt Jørgensen is involved in projects assessing the efficacy and safety of methotrexate (MTX) added to a biological agent compared with biologic monotherapy for patients with RA, and to evaluate and compare treatment efficacy with special focus on utility and tolerability among the different biologic therapies.
Dr Schjødt Jørgensen has published several articles in scientific journals with peer review.